Tectonic Therapeutic, Inc.
🇺🇸United States
Artiva's AlloNK Cell Therapy Shows Durable Response in Lymphoma Patients in Phase 1/2 Trial
• Artiva Biotherapeutics reported longer-term Phase 1/2 data for AlloNK cell therapy, demonstrating prolonged durability of response in patients with non-Hodgkin lymphoma.
• The combination therapy of AlloNK with rituximab showed promising efficacy and safety profiles, potentially offering a new treatment option for patients with relapsed or refractory lymphoma.
• Results highlight AlloNK's potential as an off-the-shelf NK cell therapy that could address limitations of current cellular immunotherapies while maintaining clinical effectiveness.
Isomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery Platform
• Isomorphic Labs raised $600 million in its first external funding round in March 2025, representing the largest private biotech investment of the month.
• The funding will accelerate the company's frontier artificial intelligence research to enhance its next-generation AI drug design engine.
• March 2025 showed strong biotech fundraising activity with over $2.2 billion raised across private and public rounds, making it the second-best month of 2025 thus far.
Eli Lilly Halts Kidney Disease Drug Trial, Raising Concerns for Tectonic Therapeutics
• Eli Lilly terminated its Phase II trial of volenrelaxin for chronic kidney disease due to a lack of foreseeable clinical benefit.
• The decision follows the discontinuation of a related heart failure study that showed no benefit in an overlapping patient group.
• Tectonic Therapeutics' stock price fell sharply due to concerns about the potential success of its similar drug, TX45.
• Analysts at Leerink Partners maintain confidence in Tectonic, citing key differences between TX45 and volenrelaxin.
Tectonic's TX45 Shows Promise for Pulmonary Hypertension Treatment, Receives Analyst Upgrade
• Leerink Partners analyst David Risinger raises Tectonic Therapeutic's price target to $118, citing TX45's potential as a best-in-class treatment for PH-HFpEF.
• TX45, a long-acting relaxin therapeutic, targets both PH-HFpEF and PH-HFrEF patient populations, addressing significant unmet medical needs in pulmonary hypertension treatment.
• Phase 1b trial results for TX45 are expected in Q1 2025, with the company's strategic expansion into PH-HFrEF patients showing strong enrollment and physician interest.
Tectonic's TX45 Shows Promise in Phase 1b Trial for Pulmonary Hypertension with HFpEF
• Tectonic Therapeutic's TX45 demonstrated significant improvements in left ventricular function and pulmonary hemodynamics in patients with PH-HFpEF.
• The Phase 1b trial showed a 17.9% reduction in pulmonary capillary wedge pressure (PCWP) in the overall study population.
• In a subpopulation with more severe disease (CpcPH), TX45 achieved a greater than 30% reduction in pulmonary vascular resistance (PVR).
• TX45 was well-tolerated, with no serious adverse events reported, supporting its continued development in the Phase 2 APEX trial.
Septerna Raises $288M in Upsized IPO to Advance Novel GPCR-Targeting Drug Pipeline
• Septerna successfully completed an upsized IPO raising $288 million, selling 16 million shares at $18 each, demonstrating strong investor confidence in clinical-stage biotech companies.
• The company's lead drug candidate SEP-786, targeting hypoparathyroidism, recently entered Phase 1 clinical trials with data expected by mid-2025.
• Septerna plans to allocate $117 million of the proceeds to advance SEP-786 and $37 million for developing SEP-631 for chronic spontaneous urticaria and mast cell conditions.
Tectonic Therapeutic's TX45 Shows Promise in Phase Ia Trial for Pulmonary Hypertension
• Tectonic Therapeutic reported positive topline data from its Phase Ia trial of TX45 for Group 2 pulmonary hypertension with preserved ejection fraction (PH-HFpEF).
• The trial demonstrated that TX45 was safe and well-tolerated in healthy subjects, with minimal adverse events and no immune-mediated clearance observed.
• A strong pharmacokinetic/pharmacodynamic (PK/PD) relationship was established, enabling the selection of appropriate doses for the upcoming Phase II trial.
• The Phase II trial, named APEX, has commenced subject screening and will evaluate the effect of TX45 on PH-HFpEF patients with topline results expected in 2026.
© Copyright 2025. All Rights Reserved by MedPath